Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 37% ± 15% | |
peripheral blood | 18 studies | 40% ± 15% | |
intestine | 11 studies | 41% ± 16% | |
eye | 10 studies | 38% ± 17% | |
kidney | 9 studies | 33% ± 14% | |
brain | 8 studies | 36% ± 11% | |
lymph node | 6 studies | 41% ± 14% | |
liver | 6 studies | 46% ± 22% | |
pancreas | 5 studies | 42% ± 19% | |
bone marrow | 5 studies | 35% ± 17% | |
uterus | 5 studies | 49% ± 13% | |
prostate | 5 studies | 38% ± 18% | |
heart | 4 studies | 24% ± 5% | |
esophagus | 4 studies | 45% ± 25% | |
breast | 4 studies | 58% ± 4% | |
placenta | 3 studies | 48% ± 22% | |
adrenal gland | 3 studies | 40% ± 17% | |
stomach | 3 studies | 39% ± 28% | |
thymus | 3 studies | 60% ± 30% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 7879.67 | 21 / 21 | 100% | 146.77 | 504 / 504 |
esophagus | 100% | 8959.28 | 1445 / 1445 | 100% | 137.16 | 183 / 183 |
intestine | 100% | 9825.39 | 966 / 966 | 100% | 132.91 | 527 / 527 |
liver | 100% | 6383.73 | 226 / 226 | 100% | 68.57 | 406 / 406 |
lung | 100% | 10020.56 | 578 / 578 | 100% | 128.93 | 1155 / 1155 |
ovary | 100% | 9554.11 | 180 / 180 | 100% | 144.14 | 430 / 430 |
skin | 100% | 9058.61 | 1809 / 1809 | 100% | 108.82 | 472 / 472 |
stomach | 100% | 7111.34 | 359 / 359 | 100% | 122.22 | 286 / 286 |
uterus | 100% | 10129.72 | 170 / 170 | 100% | 180.92 | 459 / 459 |
breast | 100% | 9636.18 | 459 / 459 | 100% | 132.09 | 1116 / 1118 |
prostate | 100% | 9447.07 | 245 / 245 | 100% | 99.51 | 501 / 502 |
thymus | 100% | 11705.49 | 653 / 653 | 100% | 108.36 | 603 / 605 |
adrenal gland | 100% | 8639.98 | 258 / 258 | 100% | 92.56 | 229 / 230 |
kidney | 100% | 8721.20 | 89 / 89 | 100% | 78.62 | 897 / 901 |
pancreas | 100% | 5294.82 | 328 / 328 | 99% | 106.75 | 177 / 178 |
brain | 99% | 5551.57 | 2617 / 2642 | 100% | 111.02 | 705 / 705 |
adipose | 100% | 9400.30 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 186.89 | 29 / 29 |
spleen | 100% | 14007.46 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 150.20 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 107.04 | 1 / 1 |
blood vessel | 100% | 7769.85 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 5373.41 | 857 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 4421.38 | 794 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 69.83 | 75 / 80 |
peripheral blood | 93% | 6465.26 | 865 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006397 | Biological process | mRNA processing |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0033197 | Biological process | response to vitamin E |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0008380 | Biological process | RNA splicing |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005726 | Cellular component | perichromatin fibrils |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0035061 | Cellular component | interchromatin granule |
GO_0005634 | Cellular component | nucleus |
GO_0005080 | Molecular function | protein kinase C binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0003723 | Molecular function | RNA binding |
GO_0036002 | Molecular function | pre-mRNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SRSF2 |
Protein name | Serine/arginine-rich splicing factor 2 (Protein PR264) (Splicing component, 35 kDa) (Splicing factor SC35) (SC-35) (Splicing factor, arginine/serine-rich 2) Serine/arginine-rich splicing factor 2 (Splicing component, 35 kDa) (Splicing factor SC35) (Splicing factor, arginine/serine-rich 2) Serine and arginine rich splicing factor 2 Serine and arginine rich splicing factor 2 transcript variant 5 |
Synonyms | SFRS2 |
Description | FUNCTION: Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment. . |
Accessions | A0A2I7N9Z4 ENST00000452355.7 [Q01130-1] ENST00000585202.5 [Q01130-1] ENST00000583836.1 ENST00000392485.2 [Q01130-1] Q01130 ENST00000358156.7 J3KP15 J3QL05 ENST00000508921.7 [Q01130-2] ENST00000359995.10 [Q01130-1] |